Automated synthesis of [89Zr]ZrCl(4), [89Zr]ZrDFOSquaramide-bisPh(PSMA) and [89Zr]ZrDFOSquaramide-TATE
Details
Publication Year 2024-05-08,Volume 9,Issue #1,Page 39
Journal Title
EJNMMI Radiopharmacy and Chemistry
Publication Type
Research article
Abstract
BACKGROUND: Automated [(89)Zr]Zr-radiolabeling processes have the potential to streamline the production of [(89)Zr]Zr-labelled PET imaging agents. Most radiolabeling protocols use [(89)Zr][Zr(ox)(4)](4-) as the starting material and oxalate is removed after radiolabeling. In some instances, radiolabeling with [(89)Zr]ZrCl(4) as starting material gives better radiochemical yields at lower reaction temperatures. In this work, a fully-automated process for production of [(89)Zr]ZrCl(4) is reported and its use for the synthesis of [(89)Zr]ZrDFOSq-bisPhPSMA and [(89)Zr]ZrDFOSq-TATE. RESULTS: A simple automated process for the isolation of [(89)Zr]ZrCl(4) by trapping [(89)Zr][Zr(ox)(4)](4-) on a bicarbonate-activated strong anion exchange cartridge followed by elution with 0.1 M HCl in 1 M NaCl was developed. [(89)Zr]ZrCl(4) was routinely recovered from [(89)Zr][Zr(ox)(4)](4-) in > 95% yield in mildly acidic solution of 0.1 M HCl in 1 M NaCl using a fully-automated process. The [(89)Zr]ZrCl(4) was neutralized with sodium acetate buffer (0.25 M) removing the requirement for cumbersome manual neutralization with strong base. The mixture of [(89)Zr]ZrCl(4) was used for direct automated radiolabeling reactions to produce [(89)Zr]Zr-DFOSquaramide-bisPhPSMA and [(89)Zr]ZrDFOSquaramide-TATE in 80-90% over all RCY in > 95% RCP. CONCLUSIONS: This method for the production of [(89)Zr]ZrCl(4) does not require removal of HCl by evaporation making this process relatively fast and efficient. The fully automated procedures for the production of [(89)Zr]ZrCl(4) and its use in radiolabeling are well suited to support the centralized and standardized manufacture of multiple dose preparations of zirconium-89 based radiopharmaceuticals.
Publisher
Springer Nature
Keywords
Automated synthesis; Radiopharmaceuticals; Zirconium-89; [89Zr]ZrCl4
Department(s)
Cancer Imaging
Open Access at Publisher's Site
https://doi.org/10.1186/s41181-024-00270-2
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-17 03:02:37
Last Modified: 2024-07-17 03:11:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙